changes in protein profiles in bortezomib applied multiple myeloma ...

More documents

Recommendations

Info

REFERENCES Aebersold, R. and Mann, M. 2003. Mass spectrometry-based proteomics. Nature 422: 198-207. Abbott, A. 1999. A post-genomic challenge: learning to read patterns of protein synthesis. Nature 402: 715-20. Adams, J. M. 2003. Ways of dying: multiple pathways to apoptosis. Genes & Development 17: 2481–2495. Adams, J. 2003. The proteasome: structure, function, and role in the cell. Cancer Treatment Reviews 29(suppl 1): 3-9. Adams, J. and Kauffman, M. 2004. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Investigation 22(2): 304-11. Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K. and Walter, P. 2008. Molecular Biology of the Cell, 5th edition, New York, Garland Science. ACS, American Cancer Society. http :// www.cancer.org / acs / groups / cid / documents / webcontent / 003121-pdf.pdf (accessed 2011). Alexanian, R., Barlogie, B. and Dixon, D. 1990. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Archives of Internal Medicine 150: 1693–1695. Anand, P., Kunnumakkara, A. B., Sundaram, C., Harikumar, K. B., Tharakan, S. T., Lai, O. S., Sung, B. and Aggarwal, B. B. 2008. Cancer is a preventable disease that requires major lifestyle changes. Pharmaceutical Research (9): 2097-116. Anderson, K. C. 2003. Multiple Myeloma: How Far Have We Come? Mayo Clinic Proceedings 78: 15-17. Anderson, K. C. 2004. The clinical potential of proteasome inhibition. European Journal of Cancer Supplements 2(6): 3–6. Anderson, L. and Seilhamer, J. 1997. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18: 533-7. Avet-Loiseau, H., Facon, T., Grosbois, B., et al. 2002. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly 89
distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99: 2185-2191. Baran, Y., Salas, A., Senkal, C. E., Gunduz, U., Bielawski, J., Obeid, L. M. and Ogretmen, B. 2007. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. The Journal of Biological Chemistry 282: 10922-10934. Barillé-Nion, S., Barlogie, B., Bataille, R., Bergsagel, P. L., Epstein, J., Fenton, R. G., Jacobson, J., Kuehl, W. M., Shaughnessy, J. and Tricot G. 2003. Advances in Biology and Therapy of Multiple Myeloma. American Society of Hematology (ASH) 248-78. Barker, J. 1999. Mass Spectrometry John Wiley & Sons, Chichester, England. Bataille, R., Boccadoro, M., Klein, B., Durie, B. and Pileri, A. 1992. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80: 733–737. Bataille, R. and Harousseau, J. L. (1997). Multiple Myeloma. New England Journal of Medicine 336: 1657-1664. Beavis, R. C. and Chait, B. T. 1989. Cinnamic acid derivatives as matrices for ultraviolet laser desorption mass spectrometry of proteins. Rapid Communication in Mass Spectrometry 3: 432-435. Beavis, R. C., Chaudhary, T. and Chait, B. T. 1992. α-cyano-4-hydroxycinnamic acid as a matrix for matrix-assisted laser desorption mass spectrometry. Organic Mass Spectrometry 27: 156-158. Bendixen, E. 2005. The use of proteomics in meat science. Meat Science 71: 138-149. Berggren, K., Chernokalskaya, E., Steinberg, T. H., Kemper, C., Lopez, M. F., Diwu, Z., Haugland, R. P. and Patton, W. F. 2000. Background-free, high sensitivity staining of proteins in one- and two-dimensional sodium dodecyl sulfatepolyacrylamide gels using a luminescent ruthenium complex. Electrophoresis 21: 2509-2521. Bergsagel, P. L. and Kuehl, W. M. 2001. Chromosome translocations in multiple myeloma. Oncogene 20(40): 5611-22. Bilir, N. 2008. Sigara ve Kanser. Vol: 1, Klasmat, Ankara, Pp: 7. Blade, J., Cibeira, M. T. and Rosinol, L. 2005. Bortezomib: A Valuable New Antineoplastic Strategy in Multiple Myeloma. Acta Oncologica 44: 440-448. Bommert, K., Bargou, R. C. and Stühmer, T. 2006. Signalling and survival pathways in multiple myeloma. European Journal of Cancer. 4 2: 1574-1580. 90
Page 1 and 2:
CHANGES IN PROTEIN PROFILES IN BORT
Page 3 and 4:
ACKNOWLEDGEMENTS First of all, with
Page 5 and 6:
ÖZET BORTEZOMĠB UYGULANAN MULTĠP
Page 7 and 8:
2.1.4.1.2. Two-Dimensional Gel Elec
Page 9 and 10:
LIST OF FIGURES Figure Page Figure
Page 11 and 12:
LIST OF TABLES Table Page Table 1.1
Page 13 and 14:
When normal cells in the body begin
Page 15 and 16:
Figure 1.2. Development of Cancer S
Page 17 and 18:
the myeloma cells does not help fig
Page 19 and 20:
A rare form of MM called Nonsecreto
Page 21 and 22:
1.2.3. Risk Factors for MM A risk f
Page 23 and 24:
of the mineralizations by adjusting
Page 25 and 26:
To measure the levels of red cells,
Page 27 and 28:
The levels of blood urea nitrogen (
Page 29 and 30:
By using the system introduced by D
Page 31 and 32:
1.2.7.2. Biology of The Proteasome
Page 33 and 34:
Figure 1.10. Ubiquitin-Proteasome P
Page 35 and 36:
Figure 1.12. Effect of Bortezomib o
Page 37 and 38:
encompasses the investigation of pr
Page 39 and 40:
of modification. Ubiquitin is a sma
Page 41 and 42:
the given cells. On the other hand,
Page 43 and 44:
is-acrylamide (N,N'-methylene-bisac
Page 45 and 46:
2.1.4.2. Detection of Protein Spots
Page 47 and 48:
ange of 600-2500 Da. This is the id
Page 49 and 50: ions resolved by the mass analyzer
Page 51 and 52: 2.1.4.5.2. Mass Analyzers Figure 2.
Page 53 and 54: There is no doubt that different ma
Page 55 and 56: mask low-quantity proteins that may
Page 57 and 58: 3.1. Materials 3.1.1. Medias CHAPTE
Page 59 and 60: 3.2.5. Cell Proliferation Assay Ant
Page 61 and 62: After 72 hour incubation period at
Page 63 and 64: eceptors of the Tumor Necrosis Fact
Page 65 and 66: The preparation of stock BSA Standa
Page 67 and 68: 3.2.6.3. Detection of the Loss of M
Page 69 and 70: centrifugation, the supernatant was
Page 71 and 72: selected symmetrically to load the
Page 73 and 74: approximately 35 ml, the volume of
Page 75 and 76: After electrophoresis was finished,
Page 77 and 78: 7 Day Two: Reduction, Alkylation, a
Page 79 and 80: CHAPTER 4 RESULTS AND DISCUSSION 4.
Page 81 and 82: % Changes in Cytoplasmic/Mitochondr
Page 83 and 84: Table 4.1. Magnified Segments of Di
Page 85 and 86: Table 4.1. Magnified Segments of Di
Page 87 and 88: After labeling, black and red color
Page 89 and 90: 78 7 8 Y2S Y3S Table 4.2. Results o
Page 91 and 92: 80 12 S4Ca Table 4.2. Results of Di
Page 93 and 94: 82 27 Y5S Table 4.2. Results of Dif
Page 95 and 96: Spot 4, Ubiquitin-conjugating enzym
Page 97 and 98: is a transcriptional repressor, but
Page 99: activity and loss of mitochondrial
Page 103 and 104: DeMartino, G. N. and Slaughter, C.
Page 105 and 106: proteomic analyses of a systematica
Page 107 and 108: Mahindraa, A., Hideshimab, T. and A
Page 109 and 110: Richardson, P. G., Hideshima, T. an
Page 111 and 112: Terpos, E. 2008. Bortezomib Directl
Page 113 and 114: A.1. RPMI-1640 Growth Medium APPEND
Page 115 and 116: Table B.1. Chemicals and Reagents U
Page 117 and 118: B.4.3. Standard Curve for BSA Table
Page 119 and 120: Urea (8M) 4.8 g CHAPS (%2) 0.2 g DT
Page 121 and 122: E. F. G. STOCK REAGENT PREPARATION
show all

changes in protein profiles in bortezomib applied multiple myeloma ...

Create successful ePaper yourself

Delete template?

Save as template?